leisure time -WSS

leisure time

author：explore 2025-10-03 00:39:49 - browse：9

Human embryonic stem cells Annie Cavanagh/Wellcome Images

The Food and Drug Administration on Thursday unveiled a series of guidelines that aim to encourage the development of promising and legitimate stem cell therapies while distinguishing them from the largely untested stem cell treatments hawked by unregulated clinics around the country.

The FDA’s guidelines have been expected and eagerly awaited by the stem cell community given the rapid proliferation of untested — and potentially unsafe — therapies around the country. Clinics promoting these therapies claim to be able to treat ailments from autism to neurodegenerative disorders to erectile dysfunction.

The guidelines also spell out how the agency will implement the regenerative medicine provisions in a behemoth law enacted last year called the 21st Century Cures Act.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

leisure time

WSS

Publishing genetic code of viruses could cause disaster

Ohio still needs to do more to protect the right to abortion

NIH chief: government has fallen behind pharma on clinical trials

Steward Health Care has deal to sell doctor network to UnitedHealth

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

focus

leisure time

focus

Drug repurposing or repositioning? The language matters

Study says nonprofit hospitals fall short in charity care spending

How to save PrEP access — and even expand it

What health policies could hitch a ride on a spending bill?

Medical leaders decry Supreme Court decision on affirmative action

NIH chief: government has fallen behind pharma on clinical trials

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Donor acceptance rates hint at racial, gender bias in heart transplants: study

focus

A letter from the executive editor: STAT UnitedHealth investigation

Patient advocates debate FDA's accelerated approval process

Patient advocates debate FDA's accelerated approval process

Food as medicine: Medically tailored meals may get standardized

FDA reorg will put new emphasis on investigations, sources say

Covid vaccine financial winners and losers, from Pfizer to Novavax

leisure time

leisure time

focus

focus